Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.

Thibault Mesplède1, Jing Leng1, Hanh Thi Pham1

  • 1McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada.

Mbio
|April 6, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short term complications and risk factors of unilateral biportal endoscopic cervical spine surgery in patients with cervical radiculopathy and myelopathy: a single center retrospective study.

Frontiers in medicine·2026
Same author

Dynamic evolution of higher alcohols from CO<sub>2</sub> on Fe<sub>3</sub>O<sub>4</sub>-Fe<sub>5</sub>C<sub>2</sub>-Cu catalytic interfaces with amorphous Ti layout.

Nature communications·2026
Same author

Acupuncture and Moxibustion Therapy Attenuates Inflammation in CCI-Induced Sciatica by Inhibiting the NF-κB Pathway.

Journal of pharmacopuncture·2026
Same author

Advance Care Planning Documentation Completeness and End-of-Life Care: Trends and Associations Using HRS 2010-2022 Data.

The American journal of hospice & palliative care·2026
Same author

First molecular evidence of Rickettsia spp. in Triatoma rubrofasciata: implications for vector ecology and zoonotic transmission.

Parasites & vectors·2026
Same author

Awareness and misconceptions of palliative care among paid, unpaid, and non-caregivers in the U.S.

BMC palliative care·2026
This summary is machine-generated.

Human immunodeficiency virus (HIV) infection persists despite antiretroviral therapy (ART). This study shows the R263K mutation in HIV-1 integrase progressively reduces integrated viral DNA levels over time in cell culture.

Area of Science:

  • Virology
  • Molecular Biology
  • Immunology

Background:

  • Human immunodeficiency virus (HIV) infection remains a persistent challenge despite decades of active antiretroviral therapy (ART).
  • ART effectively suppresses plasma viral RNA but does not eradicate the virus, as viral DNA integrates into host cell genomes.
  • Persistent viral DNA levels correlate with comorbidities and predict viral rebound after treatment interruption.

Purpose of the Study:

  • To investigate the effect of the R263K integrase substitution on integrated HIV-1 DNA levels over time.
  • To explore the potential of dolutegravir (DTG) in reducing integrated HIV DNA, given its lower susceptibility to resistance.
  • To explain the clinical observation of the R263K substitution's rarity in treatment-experienced individuals failing DTG.

Main Methods:

Keywords:
R263Khuman immunodeficiency virusintegration

Related Experiment Videos

  • Quantitative PCR was used to measure reverse transcript levels, assessing potential defects in reverse transcription.
  • HIV-1 integration levels were measured in Jurkat cells over 4-week infections using Alu-mediated quantitative PCR.
  • Infection models utilized wild-type and R263K mutant HIV-1 viruses.

Main Results:

  • The R263K mutation did not impair reverse transcription.
  • Prolonged infections with R263K mutant viruses resulted in significantly lower integrated HIV-1 DNA levels compared to wild-type viruses.
  • These findings suggest a mechanism by which R263K diminishes viral persistence.

Conclusions:

  • The R263K substitution progressively reduces integrated HIV-1 DNA in cell culture, offering a potential explanation for its low frequency in treatment failure cases.
  • These results support the investigation of dolutegravir's capacity to lower integrated HIV DNA in clinical settings.
  • Longitudinal measurement of integrated DNA in individuals treated with dolutegravir is warranted to confirm these findings.